C4 Therapeutics Announces First Patient Dosed in CFT8919 …
Nov 6, 2024 · CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-small cell lung cancer. Importantly, CFT8919 retains full activity against additional EGFR ...
C4 Therapeutics Announces Strategic Discovery Research …
Mar 4, 2024 · C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins. March 4, 2024. PDF Version. Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline.
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 …
Dec 12, 2023 · C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma. Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity. Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma …
C4 Therapeutics Announces 2024 Priorities and Extended Cash …
Jan 9, 2024 · C4 Therapeutics, Inc. Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials. Prioritization of CFT7455, CFT1946, Discovery...
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 …
Nov 5, 2024 · C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET)WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage ...
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 …
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Announces FDA Clearance of Investigational
WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Announces License and Research - GlobeNewswire
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Announces 2024 Priorities and ... - Markets Insider
Jan 9, 2024 · Key 2024 priorities include advancing the CFT7455 and CFT1946 clinical programs to value-inflection milestones, supporting CFT8919 Phase 1 development in China by partner Betta Pharmaceuticals ...
C4 Therapeutics: Generous Valuation Heading Into ... - Seeking …
Summary. C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash ...
- Some results have been removed